Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Core Insights - Madrigal is experiencing an exciting year with significant opportunities in the market due to high unmet needs for patient solutions [2] - The company has successfully launched Rezdiffra, overcoming previous industry failures to find a viable product [2] - Madrigal is building a pipeline that includes an Oral GLP-1 aimed at enhancing Rezdiffra through a fixed-dose combination [3] Company Overview - Madrigal has assembled a highly skilled team, described as the best the CEO has ever worked with, to drive the company's initiatives [3] - The company is currently in the launch phase of Rezdiffra, which is characterized as an outstanding launch [3] Market Context - There has been a historical struggle in the industry, with over 20 failed attempts to find a solution for the unmet needs in the market [2] - The successful development of Rezdiffra positions Madrigal uniquely in a market that has seen significant challenges [2]